Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.
Christopher F BellJulie PriestMarni Stott-MillerHong KanJustyna AmelioXue SongBrendan LimoneVirginia NoxonKaren H CostenbaderPublished in: Lupus science & medicine (2020)
In this study of real-world intravenous belimumab for SLE, adherence to recommended infusion schedules was low. Outpatient healthcare and associated costs were higher in the 6 months after belimumab was initiated, although inpatient costs were lower. Reasons for non-adherence with belimumab and implications should be investigated.
Keyphrases
- systemic lupus erythematosus
- healthcare
- disease activity
- health insurance
- palliative care
- mental health
- electronic health record
- glycemic control
- mass spectrometry
- machine learning
- combination therapy
- high resolution
- metabolic syndrome
- insulin resistance
- newly diagnosed
- health information
- artificial intelligence
- social media
- high speed